In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Exelixis Inc. (NASDAQ:EXEL) reported that 1globe Capital Llc. has picked up 5,437,285 of common stock as of 2017-02-15.
The acquisition brings the aggregate amount owned by 1globe Capital Llc. to a total of 5,437,285 representing a 1.9% stake in the company.
For those not familiar with the company, Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
A glance at Exelixis Inc. (NASDAQ:EXEL)’s key stats reveals a current market capitalization of 6.08 billion based on 286.46 million shares outstanding and a price at last close of $22.02 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-11, Willsey picked up 20,000 at a purchase price of $4.95. This brings their total holding to 568,273 as of the date of the filing.
On the sell side, the most recent transaction saw Lamb unload 70,000 shares at a sale price of $18.65. This brings their total holding to 73,600.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Exelixis Inc. (NASDAQ:EXEL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
